Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment

Pouessel, D, Neuzillet, Y, Mertens, LS et al. (35 more authors) (2016) Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. Annals of Oncology, 27 (7). pp. 1311-1316. ISSN 0923-7534

Abstract

Metadata

Authors/Creators:
  • Pouessel, D
  • Neuzillet, Y
  • Mertens, LS
  • van der Heijden, MS
  • de Jong, J
  • Sanders, J
  • Peters, D
  • Leroy, K
  • Manceau, A
  • Maille, P
  • Soyeux, P
  • Moktefi, A
  • Semprez, F
  • Vordos, D
  • de la Taille, A
  • Hurst, CD
  • Tomlinson, DC https://orcid.org/0000-0003-4134-7484
  • Harnden, P
  • Bostrom, PJ
  • Mirtti, T
  • Hoernblas, S
  • Loriot, Y
  • Houede, N
  • Chevreau, C
  • Beuzeboc, P
  • Shariat, SF
  • Sagalowsky, AI
  • Ashfaq, R
  • Burger, M
  • Jewett, MAS
  • Zlotta, AR
  • Broeks, A
  • Bapat, B
  • Knowles, MA https://orcid.org/0000-0002-9363-8657
  • Lotan, Y
  • van der Kwast, TH
  • Culine, S
  • van Rhijn, BWG
Copyright, Publisher and Additional Information: © The Authors, 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The version of record Pouessel, D, Neuzillet, Y, Mertens, LS, van der Heijden, MS, de Jong, J, Sanders, J, Peters, D, Leroy, K, Manceau, A, Maille, P, Soyeux, P, Moktefi, A, Semprez, F, Vordos, D, de la Taille, A, Hurst, CD, Tomlinson, DC, Harnden, P, Bostrom, PJ, Mirtti, T, Hoernblas, S, Loriot, Y, Houede, N, Chevreau, C, Beuzeboc, P, Shariat, SF, Sagalowsky, AI, Ashfaq, R, Burger, M, Jewett, MAS, Zlotta, AR, Broeks, A, Bapat, B, Knowles, MA, Lotan, Y, van der Kwast, TH, Culine, S and van Rhijn, BWG (2016) Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. Annals of Oncology. ISSN 0923-7534 is available online at: http://dx.doi.org/10.1093/annonc/mdw170
Keywords: FGFR3; mutations; heterogeneity; bladder; cancer; targeted therapy
Dates:
  • Published: July 2016
  • Accepted: 6 April 2016
  • Published (online): 18 April 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Biological Sciences (Leeds) > School of Molecular and Cellular Biology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Oncology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Section of Experimental Oncology (Leeds)
Funding Information:
FunderGrant number
Cancer Research UKC6228/A12512
Depositing User: Symplectic Publications
Date Deposited: 25 Apr 2016 11:37
Last Modified: 19 Apr 2017 00:54
Published Version: http://dx.doi.org/10.1093/annonc/mdw170
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdw170

Share / Export

Statistics